Rotigotine is an important drug used for treating Parkinson's disease and restless leg syndrome. As the demand for this medication rises globally, leading pharmaceutical organizations are ramping up Rotigotine manufacturer through strategic expansions.
Mylan
Mylan is a prominent Rotigotine manufacturer with API production facilities in India and the United States. They hold a strong market share for supplying Rotigotine to generic drug formulations.
In 2021, Mylan invested $150 million to expand Rotigotine manufacturing capacity at their India site. This enabled a 30% increase in annual output to keep up with growing demand.
Teva Pharmaceuticals
Israel-based Teva operates multiple Rotigotine API production plants worldwide, including sites in Israel, the US, Hungary, and China.
Their flagship Rotigotine facility in Israel undergoes frequent upgrades to automate synthesis and improve quality control systems using IoT technologies.
Neuland Laboratories
Indian pharmaceutical company Neuland has two Rotigotine API manufacturing facilities in Hyderabad, approved by global regulatory agencies.
They possess capabilities for custom synthesis and recently finished a large-scale expansion project doubling Rotigotine output capacity.
Other Key Producers
Other major companies with Rotigotine manufacturing factories include Beximco Pharma, Ami Life Sciences, and Cambrex. The table below summarizes production sites:
| Company | Country |
|---|---|
| Mylan | India, US |
| Teva | Israel, US, Hungary, China |
| Neuland | India |
| Beximco | Bangladesh |
This coverage of major Rotigotine manufacturers demonstrates the global scale of API production networks powering essential Parkinson's therapies worldwide. Ongoing expansion ensures supply keeps pace with rising patient needs.
